Dividendos de Glenmark Pharmaceuticals
Dividendo controles de criterios 3/6
Glenmark Pharmaceuticals es una empresa que paga dividendos con una rentabilidad actual de 0.24% que está bien cubierta por los beneficios.
Información clave
0.2%
Rentabilidad por dividendo
28%
Ratio de pago
| Rentabilidad media de la industria | 0.7% |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Beneficios por acción | -₹27.08 |
| Rentabilidad por dividendo prevista a 3 años | 0.3% |
Últimas actualizaciones de dividendos
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29Recent updates
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10Increases to Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Might Cool off for now
Sep 17Glenmark Pharmaceuticals' (NSE:GLENMARK) Dividend Will Be ₹2.50
Aug 27Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Los dividendos por acción de GLENMARK se han mantenido estables en los últimos 10 años.
Dividendo creciente: El pago de dividendos de GLENMARK ha aumentado en los últimos 10 años.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Glenmark Pharmaceuticals vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (GLENMARK) | 0.2% |
| Suelo de mercado 25% (IN) | 0.3% |
| Techo de mercado 25% (IN) | 1.2% |
| Media de la industria (Pharmaceuticals) | 0.7% |
| Previsión de analistas en 3 años (GLENMARK) | 0.3% |
Dividendo destacado: El dividendo de GLENMARK(0.24%) no es notable en comparación con el 25% inferior de pagadores de dividendos del mercado Indian (0.27%).
Alto dividendo: El (0.23%) del dividendo de GLENMARK es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado Indian (1.19%).
Pago de beneficios a los accionistas
Cobertura de los beneficios: Con su razonablemente bajo ratio de pago (27.7%), los pagos de dividendos de GLENMARK están bien cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Con su elevado ratio de pago en efectivo (233.9%), los pagos de dividendos de GLENMARK no están bien cubiertos por los flujos de caja.